EUVIMEDEUVIMED entdecken
Crossref

TP53 as a prognostic biomarker in canine lymphoma: Insights from a targeted next-generation sequencing approach

L. Aresu

Revue Vétérinaire Clinique · 2026-08 · 61 (3) · 168-169

DOI: 10.1016/j.anicom.2026.06.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revue Vétérinaire Clinique, 2026-08. Verfasst von L. Aresu.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Aresu, L. (2026). TP53 as a prognostic biomarker in canine lymphoma: Insights from a targeted next-generation sequencing approach. Revue Vétérinaire Clinique, 61(3), 168-169. https://doi.org/10.1016/j.anicom.2026.06.005

Vancouver

Aresu L. TP53 as a prognostic biomarker in canine lymphoma: Insights from a targeted next-generation sequencing approach. Revue Vétérinaire Clinique. 2026;61(3):168-169. doi:10.1016/j.anicom.2026.06.005

BibTeX
@article{Aresu2026,
  author = {Aresu, L.},
  title = {TP53 as a prognostic biomarker in canine lymphoma: Insights from a targeted next-generation sequencing approach},
  journal = {Revue Vétérinaire Clinique},
  year = {2026},
  volume = {61},
  number = {3},
  pages = {168--169},
  doi = {10.1016/j.anicom.2026.06.005}
}
Kostenlos starten →